Altered Gene Expression and DNA Damage in Peripheral Blood Cells from Friedreich's Ataxia Patients: Cellular Model of Pathology

Authors:

Abstract
The neurodegenerative disease Friedreich's ataxia (FRDA) is the most common autosomal-recessively inherited ataxia and is caused by a GAA triplet repeat expansion in the first intron of the frataxin gene. In this disease, transcription of frataxin, a mitochondrial protein involved in iron homeostasis, is impaired, resulting in a significant reduction in mRNA and protein levels. Global gene expression analysis was performed in peripheral blood samples from FRDA patients as compared to controls, which suggested altered expression patterns pertaining to genotoxic stress. We then confirmed the presence of genotoxic DNA damage by using a gene-specific quantitative PCR assay and discovered an increase in both mitochondrial and nuclear DNA damage in the blood of these patients (p<0.0001, respectively). Additionally, frataxin mRNA levels correlated with age of onset of disease and displayed unique sets of gene alterations involved in immune response, oxidative phosphorylation, and protein synthesis. Many of the key pathways observed by transcription profiling were downregulated, and we believe these data suggest that patients with prolonged frataxin deficiency undergo a systemic survival response to chronic genotoxic stress and consequent DNA damage detectable in blood. In conclusion, our results yield insight into the nature and progression of FRDA, as well as possible therapeutic approaches. Furthermore, the identification of potential biomarkers, including the DNA damage found in peripheral blood, may have predictive value in future clinical trials. Friedreich's ataxia is an inherited disease that causes progressive damage to the nervous system and affects the muscles and heart. The disease is caused by a defect in the frataxin gene, which is involved in iron homeostasis and likely protects against reactive oxygen species. In order to identify mechanisms involved in the nature and progression of the disease, we performed transcriptional profiling and measurements of mitochondrial and nuclear DNA damage on blood cells from FRDA patients. Transcriptional profiling was performed on blood samples from a cohort of 28 children compared to a control group. These data were then validated with a cohort of 14 adults with FRDA compared to a second independent control group. DNA damage was assessed on the blood samples from the 28 FRDA children, plus an additional 19 affected children, by quantitative PCR (QPCR). Transcriptional profiling revealed changes in gene expression consistent with the presence of genotoxic stress in FRDA patients. This finding was supported by the direct evidence that FRDA patients accumulated significantly higher levels of mitochondrial and nuclear DNA damage as compared to controls. The identification of potential biomarkers, including the DNA damage found in peripheral blood, may help identify therapeutic approaches for this devastating disease.

This publication has 70 references indexed in Scilit: